# Azilsartan medoxomil

## Edarbi 40mg

##### 

| 藥品代碼   | OEDA                                                                                                                                                                                                                                                                   |
|:-----------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症     | Treatment of hypertension; may be used alone or in combination with other antihypertensives.                                                                                                                                                                           |
| 用法用量   | Adult: Initial: 40 mg once daily; may increase to 80 mg once daily if necessary.                                                                                                                                                                                       |
| 肝功能異常 | 無需調整劑量                                                                                                                                                                                                                                                           |
| 腎功能異常 | 無需調整劑量                                                                                                                                                                                                                                                           |
| 禁忌       | Hypersensitivity to azilsartan medoxomil or any component of the formulation; concomitant use with aliskiren in patients with diabetes or moderate-to-severe renal impairment (GFR <60 mL/minute/1.73 m2).                                                             |
| 副作用     | Hypotension， orthostatic hypotension， Dizziness， fatigue， Diarrhea， nausea， Decreased hemoglobin， decreased hematocrit， decreased red blood cells， leukopenia (rare)， thrombocytopenia (rare)， Muscle spasm， weakness， Increased serum creatinine， Cough |
| 孕期建議   | Human data suggest risk in 2nd and 3 rd trimesters                                                                                                                                                                                                                     |
| 哺乳期建議 | Human Data Suggest Potential Toxicity                                                                                                                                                                                                                                  |

